Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

European Innovation Council · Running

THz-Skin THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission

Coordinator
Ita-Suomen Yliopisto, Finland
Runs
1 February 2026 to 31 January 2030
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
10 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101257203

What the project is doing

In the project's own words, from its summary on CORDIS.

In the EU skin cancer causes 36,000 deaths per year and €9 billion in healthcare and indirect costs. Diagnosis relies on expensive tools and specialists, thus preventing mass screening to improve patient outcomes and costs. THz-Skin addresses this by developing a platform that merges advanced detection technology with unique spectroscopic data for effective, accessible diagnostics. We build on the well established fact that cancer biomarkers manifest as spectral fingerprints in the terahertz-far infrared range.

By resolving these features from body thermal emission, we achieve real-time, zero-radiation, non-invasive, label-free cancer diagnostics – a real breakthrough in early skin cancer detection. Our platform blends high-performance, miniaturized sensors with a large, open-access spectral fingerprint library of skin conditions. Inspired by the RGB model for visible light, our Multifrequency Pixels (MFPs) decompose skin thermal emission into spectral bands in the 3-25 THz range, where biomolecular cancer signatures occur.

Our MFPs consist of compact, low-cost micromechanical bolometers fitted with frequency-selective metasurfaces, achieving high sensitivity and body thermal radiation analysis without cryogenics or bulky spectrometers. Diagnostic capabilities can be continuously improved by optimising MFP architecture and expanding our spectral library with simulated and experimental data. Our platform is designed for scalability, affordability and broad deployment in primary care settings.

It is also designed to integrate with AI diagnostic tools, adding sub-cutaneous, cancer specific information to standard camera images. To ensure real-world readiness, our system will undergo in vivo validation using animal models, demonstrating its diagnostic performance in biologically relevant conditions and paving the way to a new era in advanced skin diagnostics.

Topics

Who is involved

OrganisationCityCountryRole
Ita-Suomen YliopistoKuopioFinlandCoordinator
Sciprom SARLSaint SulpiceSwitzerlandParticipant
Consiglio Nazionale Delle RicercheRomaItalyThird party
Elettra - Sincrotrone Trieste ScpaBasovizza TriesteItalyParticipant
Fondazione Bruno KesslerTrentoItalyParticipant
Universita Degli Studi Di SalernoFisciano SaItalyParticipant
Universita Di PisaPisaItalyParticipant
Uab TeravilVilniusLithuaniaParticipant
Valstybinis Moksliniu Tyrimu Institutas Fiziniu Ir Technologijos Mokslu CentrasVilniusLithuaniaParticipant
Asteria Business Development LtdCambridgeUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI